GSTM1 and hepatocellular carcinoma: The comprehensive scenario became clearer, with pieces of evidence indicating that the HB vaccine could prevent acute HBV infection, chronic HBsAg carrier status, and even the newly discovered defective hepatitis Delta virus [17] (with the acquisition of this virus relying on the co-presence of HBsAg envelope for assembly and transmission [18]) along with hepatocellular carcinoma (HCC).